Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736642 | 1.00 | HSD17B10 (0.34) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2654910 | 0.77 | CRHBP (0.39) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL29950643 | 0.77 | ERN1 (0.34) | ERN1 | |
| SCHEMBL23887606 | 0.76 | ERN1 (0.33) | ERN1 | |
| SCHEMBL17315652 | 0.76 | ERN1 (0.31) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2226680 | 0.74 | CYP3A4 (0.35) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL29952500 | 0.74 | CYP3A4 (0.35) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1321340 | 0.74 | RRM2 (0.45) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL840004 | 0.74 | ERN1 (0.32) | ERN1 | |
| SCHEMBL29792042 | 0.74 | TGFBR1 (0.38) | GAAKDM4EALDH1A1L3MBTL1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20250236619-A1 | FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-24 | — | — | US | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2020241853-A1 | BENZOTRIAZOLE DERIVATIVE | 宇部興産株式会社 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020165776-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-20 | — | — | WO | disclosed |
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| EP-3555082-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018145620-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018109649-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | HSD17B10 373/4885GAA 1887/4885KDM4E 502/4885 |
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | HSD17B10 740/4885GAA 4054/4885KDM4E 1916/4885 |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | NFE2L2, KEAP1, BPTF | HSD17B10 1115/4885GAA 2420/4885KDM4E 2788/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | HSD17B10 852/4885GAA 2008/4885KDM4E 1751/4885 |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | HSD17B10 378/4885GAA 1803/4885KDM4E 2659/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | HSD17B10 505/4885GAA 1225/4885KDM4E 647/4885 |
| US-20250236619-A1 | FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE | WEE1, PPIF, WEE2 | HSD17B10 257/4885GAA 2580/4885KDM4E 3592/4885 |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | HTR2B, HTR3B, HTR1A | HSD17B10 740/4885GAA 4054/4885KDM4E 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.